# Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

> **NCT05653349** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 226 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia (ITP)

## Interventions

- **BIOLOGICAL:** Ianalumab
- **DRUG:** Placebo
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT05653349
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-03
- **Primary completion:** 2026-10-29
- **Final completion:** 2028-12-06
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653349, "Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05653349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*